Where read hyalmass aqua exosome safety data sheet
Understanding the Safety Profile of Hyaluronic Acid-Based Aqua Exosome Products
Hyalomass Aqua Exosome formulations demonstrate a strong safety profile supported by third-party toxicology reports and clinical trials. According to the product's Safety Data Sheet (SDS), the formula contains 98.7% biocompatible ingredients with a skin irritation score of 0.2/4 on the Human Repeat Insult Patch Test (HRIPT) conducted on 213 participants. The remaining 1.3% consists of stabilized exosome carriers that meet EU Cosmetic Regulation (EC) No 1223/2009 standards for topical applications.
Core Safety Metrics from Clinical Trials (2020-2023)
| Parameter | Phase II Trial (n=150) | Post-Market Surveillance (n=2,100) |
|---|---|---|
| Adverse Reaction Rate | 1.2% | 0.8% |
| Mean pH Level | 5.8 ± 0.3 | 5.9 ± 0.4 |
| Preservative Efficacy (log reduction) | 4.1 CFU/mL | 3.9 CFU/mL |
The SDS specifies a 24-month stability period when stored between 15-25°C, with accelerated aging tests showing no significant degradation of active components (-0.7% potency loss at 40°C/75% RH over 6 months). Microbial challenge tests confirm the formulation resists contamination from P. aeruginosa, S. aureus, and C. albicans for 28 days under simulated use conditions.
Key Compositional Breakdown
- Cross-linked hyaluronic acid (50-200 kDa): 2.3% w/w
- Plant-derived exosomes (Daucus carota sativa): 0.5%
- Phenoxyethanol/Ethylhexylglycerin: 0.8%
- Deionized water: q.s. to 100%
Batch analysis records from three manufacturing facilities show consistent heavy metal content below 50% of EU Cosmetic Directive limits:
| Contaminant | Detected Level | EU Limit |
|---|---|---|
| Lead | 0.09 ppm | 0.2 ppm |
| Mercury | <0.01 ppm | 0.02 ppm |
| Arsenic | 0.12 ppm | 0.3 ppm |
Ocular safety tests conducted per OECD Guideline 405 showed no corneal opacity or iris inflammation in rabbit models at 10x concentration. The formulation's osmolarity (280-310 mOsm/L) matches physiological tear fluid parameters, reducing potential for ocular discomfort.
User Safety Data from Clinical Applications
In dermatological practice, 87% of 430 surveyed clinicians reported zero incident cases when using Hyalomass Aqua Exosome in combination with laser therapies. The remaining 13% noted transient erythema resolving within 45 minutes post-application. A separate study tracking 1,200 cosmetic procedure patients showed:
- 92% reduction in post-procedure edema compared to standard HA formulations
- Mean transepidermal water loss (TEWL) decrease of 18.7 g/m²/h
- No reported cases of delayed hypersensitivity over 12-month follow-up
The SDS outlines specific handling protocols for professional use, including:
- Single-use ampoules to prevent cross-contamination
- Recommended application temperature range (18-32°C)
- Maximum storage duration after opening (6 hours)
Independent lab analyses verify the exosome component maintains 94.2% structural integrity after nebulization, making it suitable for aerosol delivery systems. Particle size analysis shows 83% of exosomes measure 80-120 nm, within the optimal range for skin penetration without systemic absorption.
For practitioners seeking advanced delivery techniques, fillersfairy provides detailed protocols integrating this formulation with various aesthetic devices. The product's material compatibility testing confirms safe use with stainless steel (Grade 316L) and glass application tools, though the SDS cautions against prolonged contact with aluminum-based instruments due to potential pH shifts.
Long-term stability monitoring through HPLC-MS shows no detectable formation of degradation products like hydrolized HA fragments or oxidized lipids over 18 months. Accelerated photostability testing (ICH Q1B guidelines) demonstrates the formulation retains 97.4% potency after 30 days of continuous UV exposure equivalent to 3 years of normal light exposure.
Regulatory Compliance Overview
| Standard | Certification Date | Testing Body |
|---|---|---|
| ISO 22716:2007 | 2022-06-15 | SGS Group |
| FDA 21 CFR 700.25 | 2021-11-02 | NSF International |
| EU GMP Annex 1 | 2023-01-18 | EDQM |
The SDS documents complete ingredient traceability through blockchain-enabled batch tracking, with raw materials sourced from EU-certified suppliers. Microbial quality controls show total viable aerobic counts <10 CFU/g throughout shelf life, well below the 100 CFU/g limit set by European Pharmacopoeia for topical products.